Danaher Corporation vs KLA Corp. — how do they compare? Danaher Corporation trades at $218.41 (market cap $152.87B), while KLA Corp. trades at $200.88 (market cap $256.72B). The key difference: KLA Corp. is the larger of the two by market cap, and Danaher Corporation pays the higher dividend (0.74%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and KLA Corp. for 60 Days on average.
| DHR | KLAC | |
|---|---|---|
Market Cap | $152.87B | $256.72B |
Volume | 5,228,698 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $242.05 | $301.71 |
52-Week Low | $161.91 | $98.28 |
Typical Hold Time | 69 Days | 60 Days |
Enterprise Value | $175.08B | $257.97B |
Dividend Yield | 0.74% | 0.47% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical momentum indicated by bullish moving averages. The company shows robust fundamentals with Q2 2026 EPS beating expectations at $1.05 versus $1.00 estimate, and maintains impressive profitability metrics including 35.57% net income margin and 87.5% ROE. Recent news highlights AI-driven demand boosting KLA's $12.57 billion backlog and positioning the company for continued growth in semiconductor equipment markets.
KLA presents a compelling investment case with analyst consensus price target of $223.88 representing 14% upside potential. The stock benefits from strong AI infrastructure spending and dominant market position in semiconductor inspection equipment. Key risks include competitive pressures from Applied Materials and ASML, valuation multiples above industry averages, and potential margin compression from increased R&D spending. Institutional ownership remains strong with recent acquisitions by Envestnet Portfolio Solutions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →